Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04960956 · ClinicalTrials.gov registry record
Glycosylation of Exosomes in Prostate and Urothelial Carcinoma
A clinical trial, sponsored by Indiana University.
- Terminated
- Registry status
- 13
- Enrollment target
NCT04960956: Clinical Trial study, sponsored by Indiana University.
NCT04960956 is a clinical trial that was terminated before completion, run by Indiana University. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04960956 was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to collect a urine sample from patients with prostate and urothelial (bladder) cancer and healthy volunteers who do not have cancer, so that researchers can perform studies on microcellular structures called exosomes that may eventually lead to a new type of urinary biomarker test for prostate and urothelial cancer.
Primary Outcome
xFresh urine will be collected for MALDI-TOF analysis to detect the concentration of exosome-derived glycans in the urine sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2016-10-13 |
| Est. Completion | 2017-02-02 |
Why NCT04960956 stopped before completion
NCT04960956 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04960956 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04960956 about?
NCT04960956 is a clinical study titled "Glycosylation of Exosomes in Prostate and Urothelial Carcinoma". The purpose of this study is to collect a urine sample from patients with prostate and urothelial (bladder) cancer and healthy volunteers who do not have cancer, so that researchers can perform studies on microcellular structures called exosomes that may eventually lead to a new type of urinary biom...
What is the current status of trial NCT04960956?
This trial is currently terminated. The enrollment target is 13 participants. The study started on 2016-10-13. Estimated completion is 2017-02-02.
Who is sponsoring clinical trial NCT04960956?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI